Marshall Wace, LLP Biogen Inc. Call Options Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BIIB
# of Institutions
1,047Shares Held
126MCall Options Held
1.37MPut Options Held
1.35M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.72 Billion0.07% of portfolio
-
Primecap Management CO Pasadena, CA16.2MShares$3.64 Billion2.65% of portfolio
-
Black Rock Inc. New York, NY14.1MShares$3.18 Billion0.07% of portfolio
-
State Street Corp Boston, MA6.75MShares$1.52 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.17MShares$1.16 Billion0.68% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $32.3B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...